Initially designed by Chmielewski et al., the study used the carcinoembryonic antigen (CEA)-specific CAR with the additional expression of IL-12, in vitro and in vivo models, demonstrated that IL-12-secreting CAR-T cells produced a greater pro-inflammatory response, improving T cell activation, modulated the tumor’s immune and vascular environment, and recruited additional immune cells, such as antitumor macrophages to the tumor microenvironment, significantly improving the antitumor response (46). This evidence concerns the gene CEACAM5 and neoplasm.